Medical Technology Enterprise Consortium (MTEC) -- Development of Treatments for COVID-19

Funding Agency:
Department of the Army

The goal of this RPP is to develop prototypes aimed to treat COVID-19 with the following focus area:

FOCUS AREA: Therapeutic(s) that can treat COVID-19. Treatments with potential application to the prevention of COVID-19 infection are desired. Therapeutics that can be administered in a non-hospital environment are desired. 

The MTEC will implement the “Enhanced White Paper” contracting methodology for this RPP, which will be an accelerated approach to award. Because of the nature and urgency of the program’s requirements, this streamlined approach is anticipated to be a better means to highlight company methodologies and skills required to address the technical and transition requirements. The Enhanced White Paper process requires extremely quick turnaround times by Offerors. MTEC anticipates that awards will be issued within 6 weeks of the RPP release date.  For more information regarding the requirements of the Enhanced White Paper process and template, refer to the RPP.

Enhanced White Papers Due: April 8, 2020 at Noon ET​


Agency Website

Eligibility Requirements

Offerors must be MTEC Members in good standing.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

April 8, 2020